While there are several reports evaluating FAP-targeting CAR T-cell strategies for CAF depletion in the solid TME (35, 36, 43–46), what is evident from these studies is that (i) the ‘on-target off-tumor’ cytotoxicity of FAP CAR T-cells is probably FAP scFv specific and choosing the appropriate scFv may alleviate this safety concern, and (ii) while efficiently ablating TME CAFs, FAP CAR-T treatment alone displays limited anti-tumor activity. Here, FAP is linked to neoplasm.